Dr. Mooreville is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
272 N Lansdowne Ave
Lansdowne, PA 19050Phone+1 610-259-3434Fax+1 610-259-3480
Summary
- Owner of urology private practice and inventor of multiple urologic surgical instruments used throughout the US and internationally. Founder, consultant and board member in medical device start-up company in the field of urologic instruments and diagnostic devices. Network of opinion leaders in urology and medical device companies in the US and Europe. Dedicated supporter and fund raiser for health care organizations.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Urology, 1979 - 1983
- Drexel University College of Medicine/Hahnemann UniversityInternship, Transitional Year, 1978 - 1979
- Pennsylvania State University College of MedicineClass of 1978
Certifications & Licensure
- PA State Medical License 1979 - 2024
- NJ State Medical License 1983 - 2021
- American Board of Urology Urology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 15 citationsThe Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.A. Ricco, Genevieve Manahan, Rachelle Lanciano, Alexandra L. Hanlon, Jun Yang
Frontiers in Oncology. 2016-08-23 - 11 citationsPropensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancerCaspian Oliai, Matthew Bernetich, Luther W. Brady, Jun Yang, Alexandra L. Hanlon
Journal of Radiation Oncology. 2016-01-23 - 27 citationsSBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN ...Matthew Bernetich, Caspian Oliai, Rachelle Lanciano, Alexandra L. Hanlon, John Lamond
Frontiers in Oncology. 2014-11-11
Authored Content
- GU Cancers See More Minimally Invasive Procedures and Personalized Treatment at AUA19May 2019
- GU Cancers See More Minimally Invasive Procedures and Personalized Treatment at AUA19May 2019
Professional Memberships
- Member
- Member
Other Languages
- Italian, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: